BCM
IONS icon

Boone Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Boone Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6M Buy
500,522
+82,689
+20% +$6.53M 11.51% 2
2025
Q4 		$33.1M Hold
417,833
– – 10.37% 3
2025
Q3 		$27.3M Buy
+417,833
New +$20.4M 8.96% 3

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boone Capital Management's IONS Position: Q1 2026 in Review

Boone Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 20% in Q1 2026, buying an estimated $6.53M and bringing the position to 500,522 shares worth $37.6M. The position accounts for 11.51% of the portfolio, ranked #2.

Boone Capital Management first reported a position in IONS in Q3 2025 and has held it in 3 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Boone Capital Management held 500,522 shares of Ionis Pharmaceuticals worth $37.6M as of Q1 2026.
  • Boone Capital Management bought 82,689 Ionis Pharmaceuticals shares in Q1 2026, an estimated $6.53M.
  • Ionis Pharmaceuticals made up 11.51% of Boone Capital Management's portfolio in Q1 2026, its #2 holding.
  • Boone Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.